ANVISA Approves Emtricitabine + Tenofovir Fumarate: Market Impact in Brazil
The recent ANVISA approval of Emtricitabine + Tenofovir Fumarate marks a pivotal moment for HIV treatment options in Brazil, influencing market dynamics.
Quick Answer
The recent ANVISA approval of Emtricitabine + Tenofovir Fumarate marks a pivotal moment for HIV treatment options in Brazil, influencing market dynamics.
Key Questions
- When did ANVISA approve generic emtricitabine and tenofovir for HIV treatment in Brazil?
- How many people living with HIV in Brazil could benefit from generic antiretroviral access?
- What cost savings do generic HIV medications provide under Brazilian law?
- What is the clinical profile of the emtricitabine-tenofovir combination?
ANVISA approved a generic version of emtricitabine combined with tenofovir disoproxil fumarate on May 23, 2022, expanding affordable HIV treatment options for Brazil's estimated 930,000 people living with HIV. The registration granted to Blanver Farmoquímica offers an alternative to Gilead's reference product Truvada, with Brazilian law requiring minimum 35% price discounts for generic medicines.
Contents10 sections
Key Takeaways
- May 2022 approval: ANVISA granted registration for generic emtricitabine + tenofovir disoproxil fumarate to Blanver Farmoquímica on May 23, 2022, with publication in Brazil's Official Gazette (ANVISA, 2022).
- Reference product: The generic references Truvada (Gilead Sciences), which FDA approved in 2004 for HIV treatment and 2012 for PrEP (FDA Truvada label, 2024).
- Patient population: Approximately 930,000 people live with HIV in Brazil, the majority receiving care through the Unified Health System (SUS) (UNAIDS 2024).
- Mandatory cost reduction: Brazilian law requires generic medicines to carry at least 35% discount versus reference product prices, directly reducing SUS pharmaceutical expenditures.
- Fixed-dose advantages: The combination reduces pill burden and supports treatment adherence—a critical factor for achieving viral suppression in HIV therapy.
What Did ANVISA Approve in May 2022?
On May 23, 2022, Brazil's National Health Surveillance Agency (ANVISA) granted registration for a generic fixed-dose combination containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate. The approval designated Blanver Farmoquímica as the registration holder in Brazil.
The generic pathway required Blanver to demonstrate pharmaceutical equivalence and bioequivalence to the reference product Truvada. ANVISA's generic registration process, governed by RDC nº 753/2022, mandates comprehensive bioequivalence studies, manufacturing quality documentation, and stability data. The 10-year registration validity runs from the date of publication in the Official Gazette.
How Does This Drug Combination Work?
Emtricitabine and tenofovir disoproxil fumarate belong to the nucleoside reverse transcriptase inhibitor (NRTI) class. Both drugs block HIV-1 reverse transcriptase, stopping viral replication. Emtricitabine is a cytidine analog; tenofovir disoproxil fumarate is an acyclic nucleotide analog.
The FDA-approved indications for this combination include:
- HIV-1 treatment (since 2004): In combination with other antiretroviral agents for adults and pediatric patients weighing at least 17 kg
- Pre-exposure prophylaxis or PrEP (since 2012): For at-risk adults and adolescents weighing at least 35 kg to reduce risk of sexually acquired HIV-1 infection
The Brazilian Ministry of Health's Clinical Protocol and Therapeutic Guidelines recommend this NRTI backbone as a preferred component of first-line antiretroviral regimens for adults living with HIV.
How Does Brazil Provide HIV Care?
Brazil runs one of the world's largest publicly funded HIV treatment programs through the Unified Health System (SUS). UNAIDS 2024 estimates indicate approximately 930,000 people living with HIV in Brazil, representing the largest HIV population in Latin America.
The Ministry of Health's Department of HIV/AIDS, Tuberculosis, Viral Hepatitis and Sexually Transmitted Infections coordinates antiretroviral procurement and distribution. In 2023, roughly 65,000 people initiated antiretroviral therapy, with approximately 96% receiving the preferred regimen of tenofovir/lamivudine plus dolutegravir according to Brazilian clinical guidelines.
Generic approvals like the 2022 emtricitabine-tenofovir registration directly support SUS sustainability. Brazilian pharmaceutical law (Lei nº 9.787/1999) mandates that generic products carry minimum 35% price discounts versus reference medicines. This pricing rule enables the Ministry of Health to expand treatment coverage while managing budgets.
How Does Generic Entry Impact Market Dynamics?
The entry of generic emtricitabine-tenofovir introduces price competition into Brazil's antiretroviral market. Before this approval, Gilead's Truvada served as the sole registered reference product for this combination. Generic availability enables SUS procurement teams to exercise competitive tendering, potentially reducing per-patient treatment costs.
Multiple therapeutic applications strengthen the market opportunity. Beyond HIV treatment, the combination's approved PrEP indication addresses prevention needs for high-risk populations including men who have sex with men and serodiscordant couples. Brazil's 2018 expansion of Truvada's indication to include PrEP—followed by ANVISA's registration changes in 2022—established clinical infrastructure that generic manufacturers can now access.
What Regulatory Pathway Did ANVISA Use?
ANVISA approved this product through the generic medicine registration pathway rather than the new drug application route. This pathway requires manufacturers to demonstrate:
- Pharmaceutical equivalence to the reference listed drug
- Bioequivalence through comparative pharmacokinetic studies
- Compliance with Good Manufacturing Practices (GMP)
- Stability data supporting shelf-life claims
- Complete quality control specifications
The generic registration process excludes biological products, immunotherapeutics, and certain specialized medicines. For small-molecule antiretrovirals like emtricitabine and tenofovir, the pathway offers streamlined review timelines compared to innovative drug applications.
Frequently Asked Questions
When did ANVISA approve generic emtricitabine and tenofovir for HIV treatment in Brazil?
ANVISA approved the generic combination of emtricitabine and tenofovir disoproxil fumarate on May 23, 2022, with registration granted to Blanver Farmoquímica e Farmacêutica S/A. The approval was published in Brazil's Official Gazette (Diário Oficial da União) on the same date.
How many people living with HIV in Brazil could benefit from generic antiretroviral access?
According to UNAIDS 2024 estimates, approximately 930,000 people are living with HIV in Brazil. The vast majority receive treatment through the Unified Health System (SUS), making generic drug availability critical for maintaining and expanding treatment coverage across the public health system.
What cost savings do generic HIV medications provide under Brazilian law?
Brazilian legislation mandates that generic medicines must be sold with a minimum discount of 35% compared to the reference product's maximum price set by ANVISA. This pricing requirement directly reduces treatment costs for Brazil's public health system and expands patient access to essential antiretroviral therapy.
What is the clinical profile of the emtricitabine-tenofovir combination?
Emtricitabine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that the FDA first approved in 2004 for HIV-1 treatment and in 2012 for pre-exposure prophylaxis (PrEP). The fixed-dose combination reduces pill burden, improves adherence, and is recommended as a core component of first-line antiretroviral regimens by WHO and the Brazilian Ministry of Health.
Primary Sources
- ANVISA. "Confira os novos genéricos aprovados para comercialização no Brasil." Published July 4, 2022. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2018/confira-os-novos-genericos-aprovados-para-comercializacao-no-brasil
- U.S. Food and Drug Administration. "TRUVADA (emtricitabine and tenofovir disoproxil fumarate) tablets, for oral use." Prescribing Information, revised July 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021752s064lbl.pdf
- UNAIDS. "2024 Global AIDS Update — Latin America Regional Profile." July 2024. https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update-latin-america_en.pdf
- ANVISA. "Registro de Genéricos." Regulatory guidance page, updated January 2025. https://www.gov.br/anvisa/pt-br/setorregulado/regularizacao/medicamentos/genericos/registro-de-genericos
- Ministério da Saúde do Brasil. "Indicadores Clínicos — Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis." https://indicadoresclinicos.aids.gov.br/
- ANVISA. "TRUVADA® (entricitabina + fumarato de tenofovir desoproxila): nova indicação." Published April 12, 2021. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/truvada-r-entricitabina-fumarato-de-tenofovir-desoproxila-nova-indicacao
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
